Immunome to Present at the Cantor Global Healthcare Conference

Rhea-AI Summary

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company focused on antibody therapeutics, announced that President and CEO Purnanand Sarma, Ph.D., will present at the Cantor Global Healthcare Conference on September 29, 2021, at 8:40 a.m. ET. Interested parties can access the live audio webcast through the company's Investor Relations page. Immunome leverages its human memory B cell platform to develop first-in-class therapeutics targeting oncology and infectious diseases, including COVID-19.

EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Cantor Global Healthcare Conference on Wednesday, September 29, 2021, at 8:40 a.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Immunome

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005925/en/

Immunome Contact

Corleen Roche

Chief Financial Officer

Immunome, Inc.

investors@immunome.com

Investor Contact

Laurence Watts

Managing Director

Gilmartin, LLC

laurence@gilmartinir.com

Immunome Media Contact

Megan McGrath or Nick Chang

MacDougall

781-235-3060

mmcgrath@macbiocom.com or nchang@macbiocom.com

Source: Immunome, Inc.

FAQ

What is the date and time of Immunome's presentation at the Cantor Global Healthcare Conference?

Immunome will present on September 29, 2021, at 8:40 a.m. ET.

Where can I access the live webcast for Immunome's presentation?

The live audio webcast can be accessed from the Investor Relations section of Immunome's website.

What is the focus of Immunome's therapeutic development?

Immunome focuses on developing antibody therapeutics for oncology and infectious diseases, including COVID-19.

Who is the CEO of Immunome?

The CEO of Immunome is Purnanand Sarma, Ph.D.

What platform does Immunome use for discovering therapeutics?

Immunome utilizes its proprietary human memory B cell platform to discover first-in-class antibody therapeutics.